Acquisitions Expand Verano’s Footprint to 14 States, 15 Cultivation and Production Facilities, and 150 Dispensaries Nationwide CHICAGO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Verano Holdings Corp...
Dana Holding Set to Join the S&P MidCap 400 PR Newswire NEW YORK, Jan. 20, 2015 NEW YORK, Jan. 20, 2015 /PRNewswire/ -- Dana Holding Corp. (NYSE: DAN) will replace Cubist Pharmaceuticals Inc...
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it will voluntarily withdraw the contingent value rights (CVRs) it issued under a Contingent Value Rights Agreement dated...
ZERBAXA geht bestimmte gefährliche und resistente gramnegative Bakterien anErstes in den USA unter dem GAIN-Gesetz zugelassenes Antibiotikum gegen gramnegative Bakterien Cubist...
ZERBAXA s’attaque à certaines bactéries à Gram négatif graves et résistantes Premier nouvel antibiotique approuvé aux États-Unis dans le cadre de la GAIN Act pour le traitement des...
ZERBAXA addresses certain serious and resistant Gram-negative bacteriaFirst new antibiotic approved in U.S. under the GAIN Act that treats Gram-negative bacteria Cubist...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender to purchase all outstanding shares of common stock of Cubist...
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company PR Newswire BALA...
CUBIST PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Cubist Pharmaceuticals, Inc. Over the Proposed Sale of the Company to Merck & Co. Inc...
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.005 | -5 | 0.1 | 0.105 | 0.09 | 331156 | 0.1005594 | CS |
4 | 0.02 | 26.6666666667 | 0.075 | 0.12 | 0.07 | 483367 | 0.0934675 | CS |
12 | -0.205 | -68.3333333333 | 0.3 | 0.31 | 0.0675 | 736466 | 0.12716209 | CS |
26 | -0.2 | -67.7966101695 | 0.295 | 0.42 | 0.0675 | 569203 | 0.21155878 | CS |
52 | -0.575 | -85.8208955224 | 0.67 | 0.72 | 0.0675 | 959278 | 0.40312648 | CS |
156 | -1.585 | -94.3452380952 | 1.68 | 1.76 | 0.0675 | 1043347 | 0.53318856 | CS |
260 | -1.585 | -94.3452380952 | 1.68 | 1.76 | 0.0675 | 1043347 | 0.53318856 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales